GLP-1s Spur Greater Reduction in Colorectal Cancer Risk than Aspirin
Abstract
In a large retrospective study, those taking a glucagon-like peptide 1 (GLP-1) receptor agonist drug were 36% less likely to develop colorectal cancer than those taking aspirin. Although the benefit seen for any one person was small, thousands could potentially see a benefit given the large number of people taking GLP-1s.d.
Fields of Study & Subjects
Diabetes Treatment and Management
Inflammatory mediators and NSAID effects
Colorectal Cancer Screening and Detection
Publication details
- Journal / source
- Cancer Discovery
- Publisher
- American Association for Cancer Research (AACR)
- Volume
- 16
- Issue
- 3
- Pages
- OF1–OF1
- Publication date
- 14 January 2026
- Language
- EN